IGMS — IGM Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $729.62m
- $473.24m
- $2.13m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 1.07 | 2.13 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 44.5 | 83.3 | 165 | 229 | 266 |
Operating Profit | -44.5 | -83.3 | -165 | -228 | -263 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -43.1 | -81.4 | -165 | -221 | -246 |
Provision for Income Taxes | |||||
Net Income After Taxes | -43.1 | -81.4 | -165 | -221 | -246 |
Net Income Before Extraordinary Items | |||||
Net Income | -43.1 | -81.4 | -165 | -221 | -246 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -43.1 | -81.4 | -165 | -221 | -246 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.41 | -2.65 | -4.93 | -5.32 | -4.71 |